We combine years of experience across pharma strategy, medicine development and asset evaluation with proprietary analytical technology. The result is focused, evidence-based analysis on real assets.
Our analysis starts with people who have spent their careers inside the pharmaceutical industry and in large-scale engineering.
Founder
More than 15 years across pharma, MedTech and strategy consulting, advising and leading projects at the intersection of strategy, innovation and data. He founded Tekmeria to bring predictive evidence into pharmaceutical decision-making.
Chief Technology Officer
More than 15 years designing and scaling complex technology platforms, from backend and data architecture to AI and machine-learning systems. He leads technology at Tekmeria.
Advisory Board
25 years in the pharmaceutical industry, leading strategy across oncology, biologics and vaccines at Sanofi, with extensive experience in portfolio strategy, partnerships and product launches. He advises Tekmeria as a member of its advisory board.
We help teams assess the factors that shape an asset’s development and commercial potential: the evidence, the patient populations, access and value.
Health authority decisions, clinical guidelines and comparable cases: the record of how medicines have been assessed.
Our proprietary analytical technology makes this analysis more structured, consistent and repeatable, with greater depth and speed.
These decisions have often depended on fragmented evidence and individual judgment. We give teams a firmer basis, earlier.
We are starting in oncology.
The French government’s initiative for start-ups.
The Auvergne-Rhône-Alpes region’s program for emerging innovative companies.
NVIDIA’s program for technology start-ups.
Based in Auvergne-Rhône-Alpes, France
Questions about who we are, or how we work?
Write to us